Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
KPTI > SEC Filings for KPTI > Form 8-K on 13-Jun-2014All Recent SEC Filings

Show all filings for KARYOPHARM THERAPEUTICS INC.

Form 8-K for KARYOPHARM THERAPEUTICS INC.


13-Jun-2014

Submission of Matters to a Vote of Security Holders, Other Events


Item 5.07. Submission of Matters to a Vote of Security
Holders.

Karyopharm Therapeutics Inc. (the "Company") held its Annual Meeting of Stockholders on June 9, 2014. The following is a summary of the matters voted on at that meeting.

1. The Company's stockholders elected Barry E. Greene and Mansoor Raza Mirza, M.D. as class I directors to serve until the 2017 Annual Meeting of Stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders' vote with respect to the election of such class I directors were as follows:

                                         Votes      Broker
                           Votes For    Withheld   Non-Votes
Barry E. Greene            27,628,845     894        4,543
Mansoor Raza Mirza, M.D.   27,536,979    92,760      4,543

2. The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the current fiscal year. The results of the stockholders' vote with respect to such ratification were as follows:

              Votes      Votes       Broker
Votes For    Against   Abstaining   Non-Votes
27,633,307     672        303           0



Item 8.01. Other Events.

While it was permissible in May 2014 under the applicable securities laws and the Company's insider trading policy for executive officers of the Company to purchase and sell securities of the Company, each of the executive officers listed below entered into a pre-arranged stock trading plan (a "10b5-1 Plan") pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each 10b5-1 Plan contemplates the sale of a limited number of shares of the Company's common stock for personal financial management reasons during the remainder of the 2014 calendar year.

                                                                 Maximum number of shares
                                                                 of common stock that may
Name                                        Title             be sold under such 10b5-1 Plan
Michael G. Kauffman, M.D., Ph.D.       Chief Executive                    90,000
                                     Officer and Director
   Sharon Shacham, Ph.D, MBA         President and Chief                  90,000
                                      Scientific Officer

Pursuant to each 10b5-1 Plan, certain shares of the Company's common stock held by the respective individual will be sold on a periodic basis without further direction from the individual in accordance with the terms and conditions set forth in the applicable 10b5-1 Plan, which in all cases include minimum sale price thresholds. Each 10b5-1 Plan is designed to comply with Rule 10b5-1 under the Exchange Act and the Company's insider trading policy. Transactions made pursuant to each 10b5-1 Plan will be disclosed publicly through Form 144 and Form 4 filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not undertake to report on specific Rule 10b5-1 plans of the Company's officers or directors, nor to report modifications or terminations of the aforementioned plans or the plan of any other individual.


  Add KPTI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for KPTI - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.